Table 3

Effects of alogliptin on BMI, glucose metabolism, lipid metabolism, and blood pressure

nAlogliptin treatment groupnConventional treatment groupP value
BMI at baseline (kg/m2)16124.6 ± 4.316124.9 ± 3.70.49
 Change from baseline
  26 weeks 1530.2 ± 1.31580.0 ± 1.80.18
  52 weeks1540.1 ± 1.3156−0.2 ± 1.60.037
  78 weeks 1500.2 ± 1.5153−0.2 ± 1.60.045
  104 weeks1470.3 ± 1.9150−0.3 ± 1.70.003
HbA1c at baseline (%)1587.3 ± 0.81607.2 ± 0.80.54
HbA1c at baseline (mmol/mol)15856.3 ± 8.516055.7 ± 9.30.54
 Change from baseline (HbA1c %)
  26 weeks158−0.4 ± 0.7§1600.0 ± 0.9<0.001
  52 weeks153−0.4 ± 0.6§157−0.1 ± 0.8<0.001
  78 weeks152−0.4 ± 0.8§1540.0 ± 1.1<0.001
  104 weeks150−0.3 ± 0.7§153−0.1 ± 0.80.004
Fasting blood glucose at baseline (mmol/L)1607.81 ± 1.51617.85 ± 1.930.85
 Change from baseline
  26 weeks158−0.55 ± 1.64§159−0.06 ± 2.190.026
  52 weeks150−0.59 ± 1.48§157−0.32 ± 1.810.15
  78 weeks147−0.54 ± 1.84§152−0.13 ± 2.520.11
  104 weeks149−0.45 ± 1.56§153−0.28 ± 2.030.41
Insulin at baseline (pmol/L)15857.2 ± 68.016158.3 ± 43.90.86
 Change from baseline
  52 weeks145−2.0 ± 47.3154−5.0 ± 37.00.54
  104 weeks1472.7 ± 72.81520.0 ± 43.50.70
Total cholesterol at baseline (mmol/L)1605.00 ± 0.771595.01 ± 0.750.86
 Change from baseline (%)
  26 weeks1220.0 ± 11.7138−1.7 ± 11.70.25
  52 weeks153−2.1 ± 11.4*154−3.0 ± 11.6#0.50
  78 weeks152−3.8 ± 12.4§150−3.0 ± 13.5#0.59
  104 weeks150−2.2 ± 13.9151−3.5 ± 14.4#0.43
LDL cholesterol at baseline (mmol/L)1582.89 ± 0.681602.93 ± 0.640.62
 Change from baseline (%)
  52 weeks1450.0 ± 17.1153−0.9 ± 17.30.25
  104 weeks146−0.4 ± 22.0150−2.6 ± 20.20.37
HDL cholesterol at baseline (mmol/L)1601.47 ± 0.381611.41 ± 0.360.16
 Change from baseline (%)
  26 weeks156−1.6 ± 12.9160−1.5 ± 15.80.95
  52 weeks153−2.2 ± 19.3157−1.4 ± 14.70.70
  78 weeks151−3.9 ± 12.3§1530.2 ± 16.50.015
  104 weeks149−2.0 ± 12.51531.1 ± 15.70.065
Triglyceride at baseline (mmol/L)1601.19 (0.82, 1.76)1611.25 (090, 1.68)0.31
 Change from baseline (%)
  26 weeks1510.0 (−14.7, 28.6)159−0.5 (−17.2, 23.8)0.55
  52 weeks150−7.3 (−24.4, 27.9)157−3.7 (−22.7, 23.1)0.57
  78 weeks147−6.3 (−23.5, 16.9)153−5.5 (−24.7, 19.8)0.62
  104 weeks149−1.3 (−24.3, 24.3)152−5.5 (−24.2, 19.8)0.35
Systolic BP (mmHg)161130 ± 16161132 ± 150.34
 Change from baseline
  26 weeks156−1 ± 16159−4 ± 15§0.10
  52 weeks1540 ± 16156−1 ± 160.70
  78 weeks147−1 ± 19152−4 ± 14#0.19
  104 weeks1502 ± 191520 ± 150.35
Diastolic BP (mmHg)16175 ± 1216175 ± 111.00
 Change from baseline
  26 weeks156−2 ± 10159−2 ± 11*0.62
  52 weeks154−1 ± 11156−1 ± 16*0.48
  78 weeks147−3 ± 13#152−4 ± 14§0.75
  104 weeks1500 ± 121520 ± 150.35
  • Data are mean ± SD or median (interquartile range). Differences in parameters between groups at baseline were analyzed by the Student t test or Wilcoxon rank sum test. Differences in parameters from baseline to 52 and 104 weeks within group were analyzed by one-sample t test or the Wilcoxon signed rank test. Differences in parameters from baseline to 52 and 104 weeks between groups were analyzed by the Student t test or the Wilcoxon rank sum test.

  • *P < 0.05;

  • #P < 0.01;

  • §P < 0.001.